Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients

Simona Di Giambenedetto, Michela Sali, Enrica Tamburrini, Giovanni Delogu, Roberto Cauda, Massimiliano Fabbiani, Paola Sansonetti, Andrea De Luca, Giovanni Fadda, David Kelvin

Research output: Contribution to journalArticle

27 Citations (Scopus)


Immunogenicity of influenza A (H1N1)v MF59-adjuvanted vaccine was studied in HIV-infected patients. The vaccine was effective in inducing a protective immune response in patients with a CD4 >200. cells/μL while individuals with CD4 <200. cells/μL showed lower rates of seroconversion and seroprotection. These results underscore the usefulness of immunization against influenza in HIV-infected patients, though a boosting dose of vaccine may be required in seriously immunocompromised patients. © 2011 Elsevier Ltd.
Original languageEnglish
Pages (from-to)2836-2839
Number of pages4
Publication statusPublished - 2011


  • Adjuvants, Immunologic
  • Adult
  • Antibodies, Viral
  • CD4 Lymphocyte Count
  • Female
  • HIV
  • HIV Infections
  • Hemagglutinin Glycoproteins, Influenza Virus
  • Humans
  • Immunogenicity
  • Immunology and Microbiology (all)
  • Infectious Diseases
  • Influenza A (H1N1)
  • Influenza A Virus, H1N1 Subtype
  • Influenza Vaccines
  • Influenza, Human
  • Male
  • Middle Aged
  • Molecular Medicine
  • Polysorbates
  • Public Health, Environmental and Occupational Health
  • Squalene
  • Swine flu
  • Vaccination
  • Veterinary (all)


Dive into the research topics of 'Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients'. Together they form a unique fingerprint.

Cite this